lercanidipine has been researched along with Alloxan Diabetes in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendhack, LM; Castro, MM; Fernandes, K; Gerlach, RF; Martinez, ML; Rizzi, E; Tanus-Santos, JE | 1 |
| Amenta, F; Rosenmann, E; Rosenthal, T; Tomassoni, D | 1 |
| Bolego, C; Cignarella, A; Pinna, C; Puglisi, L; Zanardo, R | 1 |
3 other study(ies) available for lercanidipine and Alloxan Diabetes
| Article | Year |
|---|---|
Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.
Topics: Alloxan; Animals; Antihypertensive Agents; Antioxidants; Aorta, Thoracic; Blood Pressure; Diabetes Mellitus, Experimental; Dihydropyridines; Enzyme Precursors; Fluorometry; Gelatinases; Gene Expression Regulation, Enzymologic; Male; Matrix Metalloproteinase 2; Oxidative Stress; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiobarbituric Acid Reactive Substances; Tissue Inhibitor of Metalloproteinase-2 | 2008 |
Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Hypertension; Kidney; Male; Rats; Renal Artery; Renal Circulation | 2007 |
Gender differences and antioxidant treatment affect aortic reactivity in short-term diabetic rats.
Topics: Acetylcholine; Animals; Antioxidants; Aorta, Thoracic; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Dihydropyridines; Female; Iloprost; In Vitro Techniques; Male; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Donors; Nitroprusside; Norepinephrine; Rats; Sex Factors; Superoxide Dismutase; Vasoconstriction; Vasodilator Agents | 2001 |